



PR Newswire

United Business Media

Frost and Sullivan Picks Epinex for Diabetes Research Award

Irvine, CA, March 17, 2009 – [Frost & Sullivan](#) will present the 2009 Excellence in Research Award in the Global Diabetes Diagnostics Market to Epinex for developing the [G1A™ Rapid Diabetes Monitoring Index Test](#). Frost & Sullivan is an internationally renowned market research and business growth consulting firm with over forty-five years of history in the global marketplace. The [award ceremony](#) will be held at the ‘Excellence in Medical Technologies & Life Sciences Banquet’ in San Francisco on Wednesday, March 18, 2009.



Frost and Sullivan will present the 2009 Excellence in Research Award in the Global Diabetes Diagnostics Market to Epinex Diagnostics for developing the G1A(TM) Test.

[This award](#) recognizes research and development programs whose “disruptive research” has the potential to revolutionize the marketplace and influence the creation and adoption of new technologies. "Award recipients are pioneers in the industry," explains Frost & Sullivan's Director of Healthcare Research Monali Patel Shastry.

Frost & Sullivan believes that Epinex’s revolutionary approach to diabetes monitoring could make a significant contribution to the diagnostic industry. According to their [report](#), the G1A™ test uses a “superior but previously unavailable marker (glycated albumin)... to create a breakthrough in the diabetes diagnostics market.” Frost & Sullivan expects Epinex to “expand globally as it continues its development of innovative cost-effective diagnostic tools.”

The G1A™ test fulfills an unmet need in diabetes monitoring. Recent research has shown that [glycated albumin](#) is a better marker for diabetics on hemodialysis, diabetics with red blood cell disorders, and women with gestational diabetes. The G1A™ test is a monthly at-home or point-of-care test that uses glycated albumin to measure the damage caused by excess sugar. It encourages preventive care and positive lifestyle changes by introducing a [monthly](#) diabetes management paradigm.

The [Asheville Project](#) has already demonstrated the health benefit and cost effectiveness of monthly diabetes monitoring by significantly improving patient health and reducing direct medical costs over a period of five years. Similar projects are now underway across the country, including a corporate wellness program developed jointly by Epinex research associate [Henna Zaidi](#) and the [American Diabetes Association](#) office in Orange County, Southern California.

About Epinex Diagnostics, Inc.

Epinex Diagnostics is a privately owned medical device company with a vision to help alleviate the current healthcare crisis through the development of innovative point-of-care technologies using rapid diagnostic tests. Please find further information about the company and the G1A™ test at www.epinex.com.

Contact:

Jacqueline Morales
Public Relations
Epinex Diagnostics, Inc.
Phone 949-660-7770, ext. 106
jacqueline@epinex.com